Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of NPX372 in Advanced Solid Tumors
NCT07563829Phase 1Recruiting
- Sponsor
- NextPoint Therapeutics
- Start
- May 2026
- Primary completion
- Apr 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NPX372 in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC) and 4 more, sponsored by NextPoint Therapeutics. Primary endpoints: Dose Limiting Toxicity at 21 days, Dose Limiting Equivalent Toxicity at 24 months and 4 more. Started May 2026; status: recruiting.
02
Drugs
NPX372
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)colorectal carcinoma (CRC)pancreatic adenocarcinoma (PDAC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07563829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07563829.